Key facts
- Seneca Therapeutics’s last known valuation is $51.0M (Jul 2025).
- It has raised $25.2M across 5 recorded rounds; the latest was Seed Round ($1.6M) in Dec 2024.
- Notable investors include Keiretsu Forum, Denniston Family Office, Accelerator Venture Partners, Broad Street Angels, Charmides Capital — 14 tracked in total.
- Seneca Therapeutics has filed 9 Form Ds with the SEC since 2019, most recently Feb 2025 ($1.6M sold to 68 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Seneca Therapeutics
Funding rounds
5 roundsAbout Seneca Therapeutics
Developer of cell-based therapies designed to offer therapeutics and vaccines for solid cancer. The company focuses on oncolytic immunotherapeutic candidates to synergize with immune checkpoint inhibitors and cancer vaccines to overcome tolerance, enabling patients to access advanced targeted treatments for all types of cancer.
- Sector
- Healthcare
- HQ
- Blue Bell, PA, United States
- Founded
- 2018
- Employees
- 10
- Website
- senecatherapeutics.com/
- Ownership
- Privately Held (backing)
Seneca Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Seneca Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Seneca Therapeutics in its N-PORT filings yet. We sweep new filings monthly.